Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, a biopharmaceutical company focused on kidney diseases, has announced participation in two upcoming investor conferences. The 22nd Annual Needham Virtual Healthcare Conference will feature a presentation on April 17 at 2:15 pm EDT, while the 2023 Bloom Burton & Co. Healthcare Investor Conference will include a fireside chat on April 25 at 10:00 am EDT. Interested parties can access live audio webcasts and archived recordings on the company's website, available for 90 days post-event. Chinook is developing precision medicines for chronic kidney diseases, with key programs focusing on atrasentan for IgA nephropathy and other therapies targeted at severe kidney disorders. The company leverages advanced research techniques to drive drug development.

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:

• 22^nd Annual Needham Virtual Healthcare Conference – Presentation on Monday, April 17^th at 2:15 pm EDT.
  
• 2023 Bloom Burton & Co. Healthcare Investor Conference – Fireside Chat on Tuesday, April 25^th at 10:00 am EDT.
  

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

What is Chinook Therapeutics announcing on April 11, 2023?

Chinook Therapeutics announced its participation in two upcoming investor conferences.

When is the presentation at the Needham Conference?

The presentation at the Needham Conference is scheduled for April 17, 2023, at 2:15 pm EDT.

What conference will Chinook participate in on April 25, 2023?

Chinook will participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023.

How can investors access the audio webcasts of Chinook's presentations?

Investors can access the audio webcasts by visiting the Investors section of Chinook's website.

What is the focus of Chinook Therapeutics?

Chinook Therapeutics focuses on developing precision medicines for kidney diseases.

What is the lead program of Chinook Therapeutics?

Chinook's lead program is atrasentan, targeting the treatment of IgA nephropathy.